Eculizumab in Posttransplant TMA: Unproven Benefit: A Response to Maritati et al.: "Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy.

Autor:	Bouwmeester RN; Radboud University Medical Center, Amalia Children's Hospital, Radboud Institute for Molecular Life Sciences, Department of Pediatric Nephrology, Nijmegen, The Netherlands., Wetzels JFM; Radboud University Medical Center, Radboud Institute for Health Sciences, Department of Nephrology, Nijmegen, The Netherlands., van de Kar NCAJ; Radboud University Medical Center, Amalia Children's Hospital, Radboud Institute for Molecular Life Sciences, Department of Pediatric Nephrology, Nijmegen, The Netherlands.
Jazyk:	angličtina
Zdroj:	Kidney international reports [Kidney Int Rep] 2024 Apr 08; Vol. 9 (6), pp. 1929. Date of Electronic Publication: 2024 Apr 08 (Print Publication: 2024).
DOI:	10.1016/j.ekir.2024.02.1442
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu